Wall Street analysts expect that Omeros Co. (NASDAQ:OMER) will report earnings of ($0.62) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Omeros’ earnings, with estimates ranging from ($0.64) to ($0.59). Omeros posted earnings of ($0.23) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 169.6%. The business is expected to report its next quarterly earnings report on Tuesday, August 14th.
On average, analysts expect that Omeros will report full year earnings of ($2.39) per share for the current fiscal year, with EPS estimates ranging from ($2.55) to ($2.22). For the next financial year, analysts forecast that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($1.91) to $0.21. Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Omeros.
Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $2.08 million. During the same quarter in the previous year, the business earned ($0.34) EPS. The company’s revenue was down 87.0% on a year-over-year basis.
Shares of Omeros traded down $0.13, reaching $18.14, during trading on Tuesday, according to MarketBeat.com. The company had a trading volume of 484,000 shares, compared to its average volume of 1,196,348. Omeros has a 12 month low of $8.36 and a 12 month high of $25.20. The firm has a market capitalization of $896.79 million, a PE ratio of -22.96 and a beta of 3.63. The company has a current ratio of 3.19, a quick ratio of 3.18 and a debt-to-equity ratio of -2.91.
In other Omeros news, VP Michael A. Jacobsen sold 23,792 shares of the stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $23.80, for a total value of $566,249.60. Following the transaction, the vice president now owns 19,480 shares in the company, valued at $463,624. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 12.10% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in the business. Principal Financial Group Inc. boosted its holdings in Omeros by 10.2% in the first quarter. Principal Financial Group Inc. now owns 29,433 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 2,723 shares in the last quarter. United Capital Financial Advisers LLC boosted its holdings in Omeros by 3.0% in the first quarter. United Capital Financial Advisers LLC now owns 104,697 shares of the biopharmaceutical company’s stock worth $1,169,000 after acquiring an additional 3,025 shares in the last quarter. Swiss National Bank boosted its holdings in Omeros by 5.3% in the first quarter. Swiss National Bank now owns 79,100 shares of the biopharmaceutical company’s stock worth $884,000 after acquiring an additional 4,000 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in Omeros by 9.0% in the fourth quarter. Baird Financial Group Inc. now owns 62,296 shares of the biopharmaceutical company’s stock worth $1,210,000 after acquiring an additional 5,151 shares in the last quarter. Finally, Teachers Advisors LLC boosted its holdings in Omeros by 7.1% in the fourth quarter. Teachers Advisors LLC now owns 80,820 shares of the biopharmaceutical company’s stock worth $1,570,000 after acquiring an additional 5,355 shares in the last quarter. Institutional investors and hedge funds own 46.09% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.